Kala Bio Announces Board and Executive Changes
Ticker: KALA · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1479419
Sentiment: neutral
Topics: board-changes, executive-compensation, governance
Related Tickers: KALA
TL;DR
KALA BIO shakes up board and exec comp - new faces, new pay structures.
AI Summary
KALA BIO, Inc. announced on February 11, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific names and dollar amounts related to these changes are not detailed in this summary section of the filing.
Why It Matters
Changes in a company's board and executive compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and executive changes can indicate internal shifts that may affect company direction and stability.
Key Numbers
- 001-38150 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-0604595 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Arlington, MA (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the departure of directors or officers?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in this section.
Who are the newly elected directors?
The filing states that directors have been elected, but their names are not provided in this summary section.
What are the key changes in compensatory arrangements for officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed here.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated February 11, 2025.
What is the principal executive office address for KALA BIO, Inc.?
The principal executive office is located at 1167 Massachusetts Avenue, Arlington, MA 02476.
Filing Stats: 704 words · 3 min read · ~2 pages · Grade level 12.3 · Accepted 2025-02-12 08:06:20
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
Filing Documents
- tm256232d1_8k.htm (8-K) — 25KB
- 0001104659-25-011852.txt ( ) — 192KB
- kala-20250211.xsd (EX-101.SCH) — 3KB
- kala-20250211_lab.xml (EX-101.LAB) — 33KB
- kala-20250211_pre.xml (EX-101.PRE) — 22KB
- tm256232d1_8k_htm.xml (XML) — 3KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Executive Officer On February 11, 2025, Mark Iwicki notified KALA BIO, Inc. (the "Company") of his decision to resign as the Chief Executive Officer of the Company, effective immediately. Following his resignation, Mr. Iwicki will continue to serve as the Chair of the Board of Directors of the Company (the "Board"). Appointment of Interim Chief Executive Officer On February 11, 2025, the Board appointed Todd Bazemore as the interim Chief Executive Officer and principal executive officer of the Company, effective immediately. Mr. Bazemore, age 54, has served as the Company's President since December 2021 and as the Company's Chief Operating Officer since November 2017. Previously, he served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc. ("Santhera"), a pharmaceutical company and subsidiary of Santhera Pharmaceuticals Holdings AG, from September 2016 until November 2017. Prior to joining Santhera, Mr. Bazemore served as Executive Vice President and Chief Commercial Officer of Dyax Corp. ("Dyax"), a biopharmaceutical company focused on orphan diseases, between April 2014 and January 2016, when Dyax was acquired by Shire plc. At Dyax, Mr. Bazemore oversaw all aspects of Dyax's commercial department including sales, marketing, commercial analytics, market access and patient services. Between April 2012 and September 2013, he served as Vice President, Managed Markets at Sunovion Pharmaceuticals, Inc. ("Sunovion") (a subsidiary of Dainippon Sumitomo Pharma Co. Ltd.), a global biopharmaceutical company focused on serious medical conditions. Prior to that, Mr. Bazemore held several roles of increasing responsibility at Sunovion, including Vice President of Sales and Vice President of Respiratory Business Unit. Since October 2020, Mr. Bazemore h
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: February 12, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary